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Carriers of the Glu167Lys coding variant in the TM6SF2 gene have recently been identified
as being more susceptible to non-alcoholic fatty liver disease (NAFLD), yet exhibit lower
levels of circulating lipids and hence are protected against cardiovascular disease. Despite
the physiological importance of these observations, the molecular function of TM6SF2
remains unknown, and no sequence similarity with functionally characterized proteins
has been identified. In order to trace its evolutionary history and to identify functional
domains, we embarked on a computational protein sequence analysis of TM6SF2. We
identified a new domain, the EXPERA domain, which is conserved among TM6SF,
MAC30/TMEM97 and EBP (D8, D7 sterol isomerase) protein families. EBP mutations
are the cause of chondrodysplasia punctata 2 X-linked dominant (CDPX2), also known as
Conradi-Hünermann-Happle syndrome, a defective cholesterol biosynthesis disorder. Our
analysis of evolutionary conservation among EXPERA domain-containing families and the
previously suggested catalytic mechanism for the EBP enzyme, indicate that TM6SF and
MAC30/TMEM97 families are both highly likely to possess, as for the EBP family, catalytic
activity as sterol isomerases. This unexpected prediction of enzymatic functions for
TM6SF and MAC30/TMEM97 is important because it now permits detailed experiments
to investigate the function of these key proteins in various human pathologies, from
cardiovascular disease to cancer.
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INTRODUCTION
Exome resequencing studies have shown great success in identify-
ing variants that cause rare Mendelian disease (Bamshad et al.,
2011). More recently, exome association studies have begun to
reveal coding variants that contribute to complex disease risk
(Do et al., 2012; Kiezun et al., 2012). To fully understand disease
pathoetiology the identification of these variants should be fol-
lowed by experimental studies that seek to reveal their effects on
biochemical pathways and cellular processes. This can be straight-
forward when much is already known about the mutated gene
and its encoded protein. Nevertheless, disease-associated coding
variants often lie within sequence or genes that are devoid of
annotated functions or features, such as currently defined motifs
or domains (Gollery et al., 2006), or they occur within human
genes whose proteins have not yet been experimentally char-
acterized. Most human proteins currently have no well-defined
molecular function (Lee et al., 2007). Even when proteins con-
tain features such as catalytic amino acids that are indicative of
enzymatic activity their substrates may remain unknown (Bartlett
et al., 2003; Galperin and Koonin, 2004; Addou et al., 2009). A
productive approach to determining the molecular functions of
Abbreviations: TM6SF2, Transmembrane 6 Superfamily Member 2; TM6SF1,
Transmembrane 6 Superfamily Member 1; MAC30, Meningioma-Associated pro-
tein 30; TMEM97, Transmembrane Protein 97; EBP, Emopamil Binding Protein;
NAFLD, Non-alcoholic Fatty Liver Disease; CDPX2, Chondro-Dysplasia Punctata
2, X-linked dominant; MEND, Male EBP Disorder with Neurological Defects.
newly-assigned disease genes is to identify, using in-depth protein
sequence analyses, homology relationships that reveal evolution-
ary relationships and domain architectures and, on occasion,
explain the molecular and cellular deficits in disease (Goodstadt
and Ponting, 2001).
Recently, a coding variant (p.Glu167Lys) in a human gene
TM6SF2 (Transmembrane 6 Superfamily Member 2) was found
to exceed genome-wide significance for association with total
cholesterol and liver fat levels (Dongiovanni et al., 2014; Holmen
et al., 2014; Kozlitina et al., 2014; Liu et al., 2014; Sookoian
et al., 2014). This amino acid substitution also explains the
genome-wide association study signals on chromosome 19p12 for
plasma triglyceride or total cholesterol levels, and for increased
myocardial infarction risk and non-alcoholic fatty liver dis-
ease (NAFLD) susceptibility (Dongiovanni et al., 2014; Holmen
et al., 2014; Kozlitina et al., 2014; Mahdessian et al., 2014;
Sookoian et al., 2014). These studies showed that TM6SF2
is expressed highly in the liver, with the Glu167Lys vari-
ant being expressed at greatly reduced levels, and that alter-
ation of its transcript’s levels in the mouse results in changes
in liver triglyceride, cholesterol, low-density and high-density
lipoprotein levels and in very-low-density lipoprotein (VLDL)
secretion.
Nevertheless, the molecular function of TM6SF2 remains
unknown, and its only distinguishing features are its predicted 10
transmembrane helices, and its localisation to the endoplasmic
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reticulum (ER) and the ER-Golgi intermediate compartment in
liver cells (Mahdessian et al., 2014). In particular, it is currently
unknown whether this protein has value of being a potential drug
target (Holmen et al., 2014), and how its variant contributes to
liver triglyceride metabolism, coronary artery disease and type
2 diabetes mellitus (Mahdessian et al., 2014). In-depth analysis
of protein sequences, so successful previously in explaining the
molecular bases of disease (for example, Sanchez-Pulido et al.,
2012; Zhang et al., 2012; Babbs et al., 2013), may shed light on
its function.
Consequently, we embarked on a computational sequence
analysis of the TM6SF protein family and identified a
novel domain (termed “EXPERA,” see below) that is present
twice in TM6SF proteins and that is also conserved among
MAC30 (Meningioma-associated protein 30; also known as
Transmembrane protein 97 [TMEM97]), and EBP (Emopamil
binding protein) protein families (Figures 1–4). These obser-
vations provide evidence that these previously uncharacterised
human proteins have, in common with EBP, an isomerase
enzymatic activity contributing to sterol metabolism.
MATERIAL AND METHODS
Multiple sequence alignments for each EXPERA domain-
containing families were generated independently with the pro-
gram T-Coffee using default parameters (Notredame et al., 2000),
slightly refined manually and visualized with the Belvu program
(Sonnhammer and Hollich, 2005). Profiles of the alignment as
global hidden Markov models (HMMs) were generated using
HMMer (Eddy, 1996; Finn et al., 2011). Profile-based sequence
searches were performed against the Uniref50 protein sequence
database (Wu et al., 2006) using HMMsearch (Eddy, 1996; Finn
et al., 2011). We used NAIL to view and analyse the HMMsearch
results, which provided a formatted view with hyper-links to
related web resources and coloring related to taxonomic informa-
tion, thus facilitating interpretation of the results (Sánchez-Pulido
et al., 2000). Remote homology analyses were performed using
FIGURE 1 | EXPERA domain-containing proteins in humans. (A)
Summary table of known function/disease relationships for all EXPERA
domain-containing proteins in humans. (B) Transmembrane topology and
common features in human members of the EXPERA domain-containing
families. Common topology for the core four transmembrane regions
(colored cylinders) present in all members of the EXPERA superfamily
(Figures 3, S1–S3). The blue oval labels the putative C-terminal ER retention
signal (lysine-rich sequence). Black circles label the most conserved position
of the EXPERA superfamily (E101 and E255 in TM6SF2, D56 in MAC30 and
D108 in EBP).
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profile-to-profile comparisons (Söding et al., 2005). The signifi-
cance of sequence-to-sequence, profile-to-sequence, and profile-
to-profile matches were evaluated in terms of an E-value, which
reflects the number of observations of better sequence matches
expected by chance. Transmembrane predictions were performed
using the TMHMM Server (Krogh et al., 2001). Figures were
generated using Inkscape (http://inkscape.org/).
RESULTS AND DISCUSSION
SEQUENCE ANALYSIS
We started by considering the number of transmembrane regions
present in TM6SF protein family members. A few members
of a second family, that of MAC30/TMEM97 proteins, are
annotated by Pfam as being homologous to TM6SF proteins
(Pfam entry: DUF2781—Domain of Unknown Function 2781)
(Bateman et al., 2010; Punta et al., 2012). This was puzzling
because ten transmembrane regions are consistently predicted for
TM6SF proteins (Figures 1, S1) whereas only four such helices are
evident for MAC30/TMEM97 proteins (Figures 1, S2). As trans-
membrane proteins often contain internal duplications (Shimizu
et al., 2004), we considered whether TM6SF proteins contain tan-
dem repeats of multiple transmembrane regions. Indeed, using
the HHpred profile-profile comparison approach (Söding et al.,
2005), and a sequence profile of the last four transmembrane
regions of TM6SF (corresponding to human TM6SF2 amino
acids 217–351), we identified statistically significant sequence
FIGURE 2 | (A) Mapping alanine-scanning mutagenesis and known disease
causing missense mutations in the EBP model. Alanine-scanning (Moebius
et al., 1999) identified 11 residues as major determinants of EBP catalytic
activity (His77, Glu81, Trp102, Tyr105, Asp109, Arg111, Tyr112, Glu123, Thr126,
Asn194, and Trp197; here renumbered to the current EBP_HUMAN
SwissProt entry numbering by subtracting one to the number of each
position). Four (orange points) are present in exactly the same positions as
are disease associated mutations (H76Y, E80K, R110Q, and W196S) and the
remaining seven (W101, Y104, D108, Y111, E122, T125, and N193) (yellow
points) are located in the vicinity of disease associated mutations (fewer than
five residues-distant). Mapped CDPX2 disease causing missense mutations
(red points), derived from Human Gene Mutation Database (HGMD) and
PubMed analysis (Stenson et al., 2003), are: M1I (Steijlen et al., 2007), M1V
(Hello et al., 2010), R62W (Herman et al., 2002), L66P (Whittock et al., 2003),
C67R (Morice-Picard et al., 2011), W68C (Lambrecht et al., 2014), C72Y
(Herman et al., 2002), I75N (Barboza-Cerda et al., 2014), H76Y (Umekoji et al.,
2008), E80K (Braverman et al., 1999; Ikegawa et al., 2000; Aughton et al.,
2003), W82C (Has et al., 2002; Shirahama et al., 2003), S98F (Tysoe et al.,
2008), S98P (Tysoe et al., 2008), E103K (Kolb-Mäurer et al., 2008), G107R
(Derry et al., 1999), R110Q (Derry et al., 1999; Hou, 2013), V119G (Non-lethal)
(Cañueto et al., 2012; Bode et al., 2013), G130V (Herman et al., 2002), S133R
(Braverman et al., 1999; Derry et al., 1999), R147G (Becker et al., 2001),
R147H (Braverman et al., 1999; Has et al., 2000; Ikegawa et al., 2000;
Shirahama et al., 2003), G157S (Herman et al., 2002), D162H (Whittock et al.,
2003), L164P (Cañueto et al., 2012), Y165C (Shirahama et al., 2003), G173R
(Herman et al., 2002), W196S (Herman et al., 2002), L203P (Has et al., 2002),
D206Y (Ausavarat et al., 2008). L18P and W47C (Milunsky et al., 2003;
Furtado et al., 2010) present a less severe phenotype called MEND (Male
EBP Disorder with Neurological Defects) syndrome (Arnold et al., 2012). (B)
Reaction catalyzed by EBP. Cholesterol carbon atoms C7, C8, and C9 are label.
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similarity with a profile generated from TM6SF transmembrane
regions three to six (corresponding to human TM6SF2 amino
acids 61–186; E = 0.03). In addition, this approach revealed sig-
nificant sequence similarity between each of these repeats and
a single repeat in the MAC30/TMEM97 family (corresponding
to human MAC30/TMEM97 amino acids 10–157; E = 6× 10−7
and 0.03; Figure 4).
By iteratively improving the phyletic coverage in each protein
family usingHMMer database searches (Eddy, 1996), we obtained
statistical significance from profile-profile comparisons that link
these three sequence families (specifically, the two TM6SF repeats
and the single MAC30/TMEM97 repeat) to the Emopamil
binding protein (EBP) family (Figures 3, 4). The significance
of these sequence similarities, their common transmembrane
helix configuration, and their shared predicted C-terminal ER
retention signal (Figures 1, 2) (Jackson et al., 1990) imply that
these domains are homologous, having derived from a common
evolutionary ancestor. We name this four transmembrane
region the EXPERA (EXPanded EBP superfamily)
domain.
FIGURE 3 | Representative multiple sequence alignment of the
EXPERA domain. Putative EBP catalytic residues (identified by
alanine-scanning) described by Moebius et al. are label in black (Moebius
et al., 1999). A mutation identified in TM6SF2 is label in red (Holmen
et al., 2014; Kozlitina et al., 2014; Sookoian et al., 2014). Human sequence
names are highlighted and the only member of the EXPERA superfamily in
Saccharomyces cerevisiae, part of the MAC30/TMEM97 family, is indicated
by a yellow box. Numbers shown in green represent inserted amino acids
that have been removed from the alignment. Different groups of the
EXPERA sequences identified by sequence similarity are shown by colored
lines to the left of the alignment: light red, TM6SF family first repeat; dark
red, TM6SF family second repeat; yellow, MAC30/TMEM97 family; purple,
EBP family. DUF2781 (in blue), previously defined in Pfam (includes
TM6SF second repeat and MAC30 family). The TMHMM helix
transmembrane (Krogh et al., 2001) consensus prediction are shown below
the alignment for each family, in red, yellow, and violet cylinders for
TM6SF (repeats 1 and 2), MAC30/TMEM97, and EBP families, respectively
(see Figures S1–S3). The limits of the protein sequences included in the
alignment are indicated by flanking residue positions. Alignments were
produced with T-Coffee, HMMer, and HHpred (Eddy, 1996; Notredame
et al., 2000; Söding et al., 2005; Finn et al., 2011) using default parameters
and slightly refined manually. The alignment was presented with the
program Belvu (Sonnhammer and Hollich, 2005) using a coloring scheme
indicating the average BLOSUM62 scores (which are correlated with amino
acid conservation) of each alignment column: red (>0.7), violet (between
0.7 and 0.4) and light yellow (between 0.4 and 0.2). Sequences are named
according to their UniProt identifications (Wu et al., 2006). Species
abbreviations: ARATH, Arabidopsis thaliana (Mouse-ear cress); ASPFC,
Neosartorya fumigata (Fungus); AURDE, Auricularia delicata (White-rot
fungus); CAEEL, Caenorhabditis elegans; CANGA, Candida glabrata (Yeast);
CHLRE, A8JGX8_CHLRE, Chlamydomonas reinhardtii (Green alga); CIOIN,
Ciona intestinalis; CRAGI, Crassostrea gigas (Pacific oyster); DEBHA,
Debaryomyces hansenii (Yeast); DICDI, Dictyostelium discoideum (Slime
mold); EMIHU, Emiliania huxleyi (Chromalveolata); HUMAN, Homo sapiens;
LOTGI, Lottia gigantea (Giant owl limpet); MALGO, Malassezia globosa
(Fungus); MONBE, Monosiga brevicollis (Choanoflagellate); NAEGR,
Naegleria gruberi (Amoeba); NEMVE, Nematostella vectensis (Starlet sea
anemone); NEUCR, Neurospora crassa (Fungus); OSTTA, Ostreococcus
tauri (Green alga); PHACS, Phanerochaete carnosa (Fungus); PICPG,
Komagataella pastoris (Yeast); PIRID, Piriformospora indica (Fungus);
SALR5, Salpingoeca rosetta (Choanoflagellate); SCHPO,
Schizosaccharomyces pombe (Fission yeast); SELML, Selaginella
moellendorffii (Spikemoss); STRPU, Strongylocentrotus purpuratus (Purple
sea urchin); THAPS, Thalassiosira pseudonana (Marine diatom); TRIAD,
Trichoplax adhaerens; VOLCA, Volvox carteri (Green alga); YARLI, Yarrowia
lipolytica (Yeast); YEAST, Saccharomyces cerevisiae (Baker’s yeast).
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FIGURE 4 | HHpred comparison E-values. The numbers correspond to
E-values from HHpred (Söding et al., 2005) profile searches against a Pfam
profile database which includes profiles that represent families shown in
the figure. Profile-to-profile matches were evaluated in terms of an E-value,
which is the expected number of non-homologous proteins with a score
higher than that obtained for the database match. An E-value much lower
than one indicates statistical significance. Solid lines represent statistically
significant sequence similarity relationships, e.g., the MAC30/TMEM97
family calibrated profile finds with 0.003 and 0.03 E-values the profiles of
EBP family and TM6SF first EXPERA repeat, respectively. The black dotted
line between TM6SF second EXPERA domain repeat and EBP shows the
unique relationship found with a non-highly significant value (E-value 1.2).
The sequence similarity between TM6SF (second EXPERA domain repeat)
and MAC30/TMEM97 families (presented inside the blue dotted oval) was
already described in a DUF (Domain of Unknown Function) entry of Pfam
(DUF2781, Pfam family identification: PF10914) (Bateman et al., 2010;
Punta et al., 2012).
FUNCTION PREDICTION
As for the TM6SF family, the molecular function of
MAC30/TMEM97 is currently poorly understood. Nevertheless,
because of its wide phyletic distribution in eukaryotes (in plants,
metazoa and fungi) it is likely to have a fundamental cellular
function. As expected from our sequence analysis, it is mainly
localized in the ER (Huh et al., 2003; Matsuyama et al., 2006).
Under sterol-depleted conditions, however, it becomes enriched
in the endo-lysosomal compartment where it interacts with
NPC1 (Niemann-Pick disease, type C1 Protein) and regulates
cellular cholesterol levels (Wilcox et al., 2007; Bartz et al., 2009).
In a variety of cancers, elevated MAC30/TMEM97 expression
has been directly related to unfavorable prognosis, and its
down-regulation inhibits the proliferation of gastric cancer cells
(Kayed et al., 2004; Zhang et al., 2006; Moparthi et al., 2007; Yan
et al., 2010; Zhao et al., 2011; Han et al., 2013; Xiao et al., 2013;
Yang et al., 2013; Xu et al., 2014).
The only member of the EXPERA superfamily with known
molecular function is EBP, an enzyme with a 8, 7 sterol
isomerase activity that catalyzes the transposition of a double
bond from C8 = C9 to C7 = C8 in the sterol B-ring (Figure 2)
(Wilton et al., 1969; Akhtar et al., 1970; Silve et al., 1996; Bae et al.,
2001; Nes et al., 2002; Rahier et al., 2008).
EBP forms homotetramers (Nes et al., 2002) and higher-order
protein complexes with sterol 7 reductase (DHCR7), catalyzing
and regulating key steps in the final cholesterol biosynthesis path-
way (Kedjouar et al., 2004; de Medina et al., 2010; Silvente-Poirot
and Poirot, 2012). Mutations in EBP cause Conradi-Hünermann-
Happle syndrome (also known as Chondrodysplasia punctata
type II disease), a rare X-linked dominant disorder character-
ized by skeletal malformations, skin abnormalities, cataracts, and
short stature (Braverman et al., 1999; Derry et al., 1999; Has et al.,
2000, 2002; Cañueto et al., 2012, 2014).
Based on consensus transmembrane predictions over the
expanded EBP family and superfamily (EXPERA domain-
containing proteins) (Figures 3, S3) we generated a five trans-
membrane EBP model (Figures 1, 2), that adds to and reconciles
the main features of previously proposed four transmembrane
EBP models (Hanner et al., 1995; Moebius et al., 1997, 2000;
Dussossoy et al., 1999). Our model is in agreement with a lume-
nal localisation of the EBP N-terminal region (Dussossoy et al.,
1999), and with a cytoplasmic localisation of its predicted C-
terminal ER retention motif (Jackson et al., 1990; Hanner et al.,
1995; Moebius et al., 1997, 2000). Mapping alanine-scanning
mutagenesis variants (Moebius et al., 1999) and known disease-
causing missense mutations (Figure 2) onto the EBP model,
predict that the luminal, and transmembrane portions of the EBP
EXPERA domain contain the greater fraction of key functional
sites (Figures 2, 3).
Several of these sites, previously proposed contain catalytic
residues (Moebius et al., 1999), are conserved not just in EBP
orthologues but also across the EXPERA domain superfam-
ily (Figure 3). Conservation of acidic amino acids at positions
80 and 108 (human EBP numbering) strongly suggests their
involvement in catalysis involving sterols across all members
of this superfamily. How these residues might catalyze sterol
isomerisation is unclear, but may be similar to the enzymatic
action of ketosteroid isomerases for which acidic residues (Asp
or Glu) act as a proton donor or acceptor (Pollack, 2004;
Sharma et al., 2006). EBP’s proposed catalytic mechanism ini-
tially involves C-9 protonation of the steroid molecule, with the
subsequent generation of a carbonium ion at C-8, and finally
the elimination of a proton from C-7 (Wilton et al., 1969;
Nes et al., 2002; Rahier et al., 2008) (Figure 1). It is possible
that the conserved acidic residues in other EXPERA domain
proteins, including MAC30/TMEM97 and TM6SF1/2, catalyze
a similar sterol isomerisation reaction as proton donors and
acceptors.
The homologous relationships described here between
TM6SF2 and EBP could also explain the reported side-effects
of tamoxifen (Oien et al., 1999; Hackshaw et al., 2011),
which is an antagonist of the estrogen receptor commonly
used in breast cancer therapy (Jordan, 2000). Drug cross-
reactivity among homologous proteins frequently underlies
undesired pleiotropic effects (Searls, 2003; Campillos et al.,
2008).
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Tamoxifen is a known inhibitor of EBP (Moebius et al., 1998;
Kedjouar et al., 2004; de Medina et al., 2010; Silvente-Poirot and
Poirot, 2012), and if its homolog TM6SF is similarly inhibited by
tamoxifen then this would result in a reduction of total choles-
terol level and the induction of NAFLD (Holmen et al., 2014;
Kozlitina et al., 2014; Liu et al., 2014; Sookoian et al., 2014) which
are precisely the known side-effects of tamoxifen administration
(Oien et al., 1999; Hackshaw et al., 2011).
MAC30/TMEM97 is expressed at high levels in breast, esoph-
agus, stomach, and colon cancers (Kayed et al., 2004). Human
gastric cancer cells are known to have reduced cellular prolif-
eration and mobility when MAC30/TMEM97 transcript levels
are down-regulated (Xu et al., 2014). This implies that the inhi-
bition of MAC30/TMEM97 catalytic activity by tamoxifen may
also lead to reduced proliferation of cancer cells. Identification
of the EXPERA domain family may thus help to elucidate the
complex interplay between cancer and cholesterol metabolism
(Silvente-Poirot and Poirot, 2014).
In summary, our analyses have identified TM6SF1, TM6SF2,
and MAC30/TMEM97 as EBP homologs. This indicates that
these proteins are all likely to possess similar catalytic activi-
ties, potentially as sterol isomerases. These results provide new
opportunities for their experimental characterization, and for
the development of drugs that would inhibit members of the
EXPERA superfamily.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fgene.
2014.00439/abstract
We include as Supplementary Material three full-length
multiple sequence alignments of representative sequences
and transmembrane predictions for the EXPERA domain-
containing families: TM6SF, MAC30/TMEM97 and EBP
(Figures S1–S3).
Figure S1 | TM6SF family representative full-length alignment and
transmembrane prediction. The sequence variant identified in TM6SF2 is
labeled in red (Holmen et al., 2014; Kozlitina et al., 2014; Sookoian et al.,
2014). EXPERA domains limits are marked with red bars (light red for the
first repeat and dark red for the second repeat) above the alignment. The
most conserved positions of both EXPERA domains (E101 and E255) are
labeled. TMHMM helix transmembrane (Krogh et al., 2001) predictions are
shown below each input sequence (consensus of these predictions is
shown in Figure 3). The alignment was presented with the program Belvu
(Sonnhammer and Hollich, 2005) using a coloring scheme indicating the
average BLOSUM62 scores (which are correlated with amino acid
conservation) of each alignment column: black (>3), gray (between 3 and
1.5) and light gray (between 1.5 and 0.5). Sequences are named according
to their UniProt identifications (Wu et al., 2006). Human proteins
identifications are underlined in red (TM6SF2, Q9BZW4_HUMAN and
TM6SF1, Q9BZW5_HUMAN). Species abbreviations: CALMI,
Callorhynchus milii (Australian ghost shark); CIOIN, Ciona intestinalis;
CRAGI, Crassostrea gigas (Pacific oyster); HUMAN, Homo sapiens;
MONBE, Monosiga brevicollis (Choanoflagellate); ORENI, Oreochromis
niloticus (Nile tilapia); SALR5, Salpingoeca rosetta (Choanoflagellate);
STRPU, Strongylocentrotus purpuratus (Purple sea urchin); TETUR,
Tetranychus urticae (Chelicerata); XENTR, Xenopus tropicalis.
Figure S2 | MAC30 family representative full-length alignment and
transmembrane prediction. The extent of the EXPERA domain is marked
with a yellow bar above the alignment. The most conserved position of
the EXPERA superfamily (D56) is labeled. TMHMM helix transmembrane
(Krogh et al., 2001) predictions are shown below each input sequence
(consensus of these predictions is shown in Figure 3). The alignment was
presented with the program Belvu (Sonnhammer and Hollich, 2005) using
a coloring scheme indicating the average BLOSUM62 scores (which are
correlated with amino acid conservation) of each alignment column: black
(>3), gray (between 3 and 1.5) and light gray (between 1.5 and 0.5).
Sequences are named according to their UniProt identifications (Wu et al.,
2006). MAC30/TMEM97 human protein identification is underlined in
yellow (Q5BJF2_HUMAN). Species abbreviations: 9CHLO, Coccomyxa
subellipsoidea; ACACA, Acanthamoeba castellanii; ARATH, Arabidopsis
thaliana (Mouse-ear cress); BYSSP, Byssochlamys spectabilis; CANAW,
Candida albicans; CLAL4, Clavispora lusitaniae; COCIM, Coccidioides
immitis; DEBHA, Debaryomyces hansenii (Yeast); HUMAN, Homo
sapiens; LOTGI, Lottia gigantea (Giant owl limpet); MARBU, Marssonina
brunnea; MICGM, Mycosphaerella graminicola; MICPC, Micromonas
pusilla; MUSAM, Musa acuminata; PHATC, Phaeodactylum tricornutum;
PICPG, Komagataella pastoris (Yeast); PICSI, Picea sitchensis; PICST,
Scheffersomyces stipitis; PRUPE, Prunus persica; PSED2,
Pseudogymnoascus destructans; SCHPO, Schizosaccharomyces pombe
(Fission yeast); SELML, Selaginella moellendorffii (Spikemoss); TRIAD,
Trichoplax adhaerens; VOLCA, Volvox carteri (Green alga); XENTR,
Xenopus tropicalis; YEAST, Saccharomyces cerevisiae (Baker’s yeast).
Figure S3 | EBP family representative full-length alignment and
transmembrane prediction. The extent of the EXPERA domain is marked
with a violet bar above the alignment. The most conserved position of the
EXPERA superfamily (D108) is labeled. TMHMM helix transmembrane
(Krogh et al., 2001) predictions are shown below each input sequence
(consensus of these predictions is shown in Figure 3). The alignment was
presented with the program Belvu (Sonnhammer and Hollich, 2005) using
a coloring scheme indicating the average BLOSUM62 scores (which are
correlated with amino acid conservation) of each alignment column: black
(>3), gray (between 3 and 1.5) and light gray (between 1.5 and 0.5).
Sequences are named according to their UniProt identifications (Wu et al.,
2006). Human proteins identifications are underlined in violet (EBP,
Q15125_HUMAN and EBPL, Q9BY08_HUMAN). Species abbreviations:
9AGAR, Moniliophthora roreri; 9GLOM, Rhizophagus irregularis; ACACA,
Acanthamoeba castellanii; ARATH, Arabidopsis thaliana (Mouse-ear
cress); ASPO3, Aspergillus oryzae; BRAFL, Branchiostoma floridae
(Amphioxus); CAEEL, Caenorhabditis elegans; CAPO3, Capsaspora
owczarzaki; COPC7, Coprinopsis cinerea; CRAGI, Crassostrea gigas
(Pacific oyster); HUMAN, Homo sapiens; LOTGI, Lottia gigantea (Giant owl
limpet); MAGO7, Magnaporthe oryzae; MONDO, Monodelphis domestica
(opossum); NAEGR, Naegleria gruberi (Amoeba); PHACS, Phanerochaete
carnosa; RHOT1, Rhodosporidium toruloides; SELML, Selaginella
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moellendorffii (Spikemoss); STRPU, Strongylocentrotus purpuratus (Purple
sea urchin); TALSN, Talaromyces stipitatus; TRIAD, Trichoplax adhaerens;
VERA1, Verticillium alfalfae.
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